Duloxetine Mini-Tablet Enteric Coating for Acid Stability
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Duloxetine is prone to acid-catalyzed hydrolysis and water hydrolysis, leading to degradation and reduced bioavailability, especially in acidic stomach environments, necessitating a stable and bioavailable oral pharmaceutical formulation that prevents premature disintegration and maintains consistent drug release.
Innovation Solution
A delayed release pharmaceutical composition comprising a core of Duloxetine with a separating layer and an enteric coating, applied in the form of mini-tablets within a hard gelatin capsule, using a dry granulation process to prevent interactions with acidic polymers and ensure stability and bioavailability, with the separating layer composed of water-soluble agents like hydroxypropylmethyl cellulose and the enteric layer using hydroxypropylmethylcellulose acetate succinate.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of operation
If Duloxetine is formulated as an oral solid dosage form, then it provides convenient administration and extended release, but it undergoes acid-catalyzed hydrolysis in the stomach leading to degradation and reduced bioavailability
Solution Approach 1:
The tablet is segmented into multiple functional layers: a core layer containing Duloxetine, a separating layer comprising water-soluble inorganic salt crystals, and an enteric coating layer. This segmentation protects the drug from acidic degradation while enabling controlled release.
Solution Approach 2:
A separating layer comprising water-soluble inorganic salt crystals (such as sodium chloride, potassium chloride, or calcium chloride) is introduced as an intermediary between the Duloxetine core and the enteric coating. This separating layer prevents direct contact between the enteric polymer and Duloxetine, eliminating acid-catalyzed hydrolysis while maintaining delayed release functionality.
2Reliability
If an enteric coating is applied to prevent premature disintegration in the stomach, then bioavailability is improved, but the formulation complexity and manufacturing difficulty increase
Solution Approach 1:
Different regions of the tablet have different properties: the core layer provides drug release, the separating layer provides chemical stability by preventing acid-catalyzed hydrolysis, and the enteric coating provides site-specific release in the intestine. Each layer is optimized for its specific function.
Solution Approach 2:
The tablet uses composite material structure combining organic polymer (enteric coating), inorganic salt crystals (separating layer), and active pharmaceutical ingredient (Duloxetine core). This composite structure provides both protection from degradation and controlled release functionality.
3Reliability
If a separating layer is introduced to stabilize Duloxetine, then degradation is prevented, but the manufacturing process becomes more complex
Solution Approach 1:
The water-soluble inorganic salt crystals in the separating layer serve a dual function: they physically separate the enteric coating from the Duloxetine core to prevent acid-catalyzed hydrolysis, and they facilitate the manufacturing process by providing a free-flowing granular layer that aids in uniform coating application.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The composition achieves stable and controlled release of Duloxetine, maintaining bioavailability and stability over an extended period, avoiding degradation in acidic conditions and ensuring consistent pharmacokinetic profiles, with improved manufacturing efficiency and cost-effectiveness.
Implementation Method 1
Duloxetine is prone to acid-catalyzed hydrolysis, which results in the formation of potentially harmful degradation products and a decrease in the bioavailability of Duloxetine
Implementation Method 2
choose an enteric coating comprising a polymer or other material which prevents premature disintegration of Duloxetine in the acidic environment of the stomach
Implementation Method 3
a separating layer comprising a water soluble inorganic salt in the form of crystals
Data Source
AI summary
The present invention relates to a stable pharmaceutical formulation for oral administration comprising a therapeutically effective amount of a serotonin-norepinephrine reuptake inhibitor or a pharmaceutically acceptable salt thereof, in particular Duloxetine that inhibits degradation and/or hydrolysis of the active ingredient. It also relates to a process for the preparation thereof.